Literature DB >> 22795647

TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2.

Harald Schwarz1, Gernot Posselt, Philipp Wurm, Matthias Ulbing, Albert Duschl, Jutta Horejs-Hoeck.   

Abstract

Pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) and NOD-like receptors (NLRs) are important sensors of microbial products. Although they are referred to as innate immune receptors, they make essential contributions to adaptive immune responses by activating dendritic cells (DCs). Simultaneous activation of DCs via different classes of PRRs provides a powerful tool for inducing strong immune responses. In the present study we investigate the interplay of the NLRs NOD1 and NOD2 and their crosstalk with TLR signaling in terms of DC-activation. We found strong synergistic effects upon treatment with NOD1 and NOD2 ligands combined with the TLR7/8 agonist R848. Simultaneous stimulation of monocyte-derived DCs resulted in highly increased production of IL-1β, IL-23 and SOCS2, a member of the suppressor of cytokine signaling (SOCS) family. Silencing of SOCS2 resulted in enhanced IL-23 expression, indicating that SOCS2 is involved in the regulation of TLR/NOD-dependent cytokine secretion. Finally, we demonstrate that TLR7/8-, NOD1- and NOD2-activated DCs promote CD4+ T cells to release increased amounts of IL-17. These results demonstrate that cooperative activation of DCs with NOD1 and NOD2 agonists and TLR7/8 ligands results in a synergistic release of pro-inflammatory mediators which promote the activation of IL-17-producing T cells.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795647     DOI: 10.1016/j.imbio.2012.06.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  15 in total

1.  Macrophages polarization is mediated by the combination of PRR ligands and distinct inflammatory cytokines.

Authors:  Lili Zhou; Xixi Cao; Jie Fang; Yuhong Li; Mingwen Fan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 2.  Linking diet to acne metabolomics, inflammation, and comedogenesis: an update.

Authors:  Bodo C Melnik
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-07-15

Review 3.  Licensing Adaptive Immunity by NOD-Like Receptors.

Authors:  Dong Liu; Anne Marie Rhebergen; Stephanie C Eisenbarth
Journal:  Front Immunol       Date:  2013-12-27       Impact factor: 7.561

Review 4.  Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria.

Authors:  Javier Oviedo-Boyso; Alejandro Bravo-Patiño; Víctor M Baizabal-Aguirre
Journal:  Mediators Inflamm       Date:  2014-12-01       Impact factor: 4.711

5.  Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells.

Authors:  Harald Schwarz; Maria Schmittner; Albert Duschl; Jutta Horejs-Hoeck
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

6.  Current knowledge and future directions of TLR and NOD signaling in sepsis.

Authors:  Niamh M Foley; Jian Wang; H Paul Redmond; Jiang Huai Wang
Journal:  Mil Med Res       Date:  2015-01-07

Review 7.  Beyond pattern recognition: NOD-like receptors in dendritic cells.

Authors:  Jayendra Kumar Krishnaswamy; Thach Chu; Stephanie C Eisenbarth
Journal:  Trends Immunol       Date:  2013-01-23       Impact factor: 16.687

Review 8.  TLR8: the forgotten relative revindicated.

Authors:  Jorge L Cervantes; Bennett Weinerman; Chaitali Basole; Juan C Salazar
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

9.  The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

Authors:  David J Dowling; Zhen Tan; Zofia M Prokopowicz; Christine D Palmer; Maura-Ann H Matthews; Gregory N Dietsch; Robert M Hershberg; Ofer Levy
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses.

Authors:  Alice Gutjahr; Laura Papagno; Fabienne Vernejoul; Thierry Lioux; Fabienne Jospin; Blandine Chanut; Eric Perouzel; Nicolas Rochereau; Victor Appay; Bernard Verrier; Stéphane Paul
Journal:  EBioMedicine       Date:  2020-07-30       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.